Clinical cornerstone最新文献_第7页

CME Test Answer Sheet and Evaluation Form for Management and prevention of glucose dysregulation 管理和预防血糖异常的CME测试答卷和评估表

Clinical cornerstone Pub Date : 2007-01-01 Epub Date: 2007-12-23 DOI: 10.1016/S1098-3597(07)80021-4

引用次数: 0

CME test answer sheet and evaluation form for cardiometabolic risk and risk management CME测试答卷及心脏代谢风险及风险管理评估表

Clinical cornerstone Pub Date : 2007-01-01 Epub Date: 2008-04-29 DOI: 10.1016/S1098-3597(07)80033-0

引用次数: 0

Type 2 diabetes mellitus is associated with multiple cardiometabolic risk factors 2型糖尿病与多种心脏代谢危险因素相关

Clinical cornerstone Pub Date : 2007-01-01 Epub Date: 2008-04-29 DOI: 10.1016/S1098-3597(07)80028-7

John E. Gerich MD

{"title":"Type 2 diabetes mellitus is associated with multiple cardiometabolic risk factors","authors":"John E. Gerich MD","doi":"10.1016/S1098-3597(07)80028-7","DOIUrl":"10.1016/S1098-3597(07)80028-7","url":null,"abstract":"<div><p>The risk for cardiovascular disease (CVD) is multifactorial and includes such risk factors as diabetes, hypertension, smoking, and dyslipidemia. Thus, targeting the hyperglycemia in type 2 diabetes mellitus (DM) alone will not eliminate all of the excess cardiovascular risk; rather aggressive treatment is needed for all of the modifiable cardiometabolic risk factors. Therapeutic lifestyle change is considered primary therapy for hyperglycemia in type 2 DM. Currently, however, the focus in treatment is on preventing CVD rather than controlling glucose, lipid, or blood pressure (BP) levels. The American Diabetes Association guidelines identify low-density lipoprotein cholesterol as the first priority of lipid lowering, with optimal level set at <100 mg/dL (2.6 mmol/L). To reach the target BP level of <130/85 mm Hg, >65% of patients with DM and hypertension will require 2 or more different antihypertensive drugs. Strategies that combine thiazolidinediones and statins may have complementary effects on cardiovascular risk-factor profiles in type 2 DM, in addition to controlling glycemia. Despite the range of treatment options available, therapeutic agents that target new steps in the progression of CVD are needed, as patients with type 2 DM remain at increased risk and many do not achieve therapeutic targets with the drugs available.</p></div>","PeriodicalId":80265,"journal":{"name":"Clinical cornerstone","volume":"8 3","pages":"Pages 53-68"},"PeriodicalIF":0.0,"publicationDate":"2007-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S1098-3597(07)80028-7","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"27417671","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 32

CME Test Answer Sheet and Evaluation Form for Insulin Therapy in Type 2 Diabetes Volume 8, Number 2 2型糖尿病胰岛素治疗CME测试答卷和评估表第8卷，第2号

Clinical cornerstone Pub Date : 2007-01-01 Epub Date: 2009-05-03 DOI: 10.1016/S1098-3597(09)60011-9

引用次数: 0

Obstructive sleep-disordered breathing in children. 儿童阻塞性睡眠呼吸障碍。

Clinical cornerstone Pub Date : 2007-01-01 DOI: 10.1016/s1098-3597(07)80004-4

Michael Benninger, David Walner

引用次数: 47

Advances in Cardiometabolic Health 心脏代谢健康研究进展

Clinical cornerstone Pub Date : 2007-01-01 Epub Date: 2007-12-22 DOI: 10.1016/S1098-3597(07)80008-1

引用次数: 0

CME Test Questions Advances in cardiometabolic health 心血管代谢健康的研究进展

Clinical cornerstone Pub Date : 2007-01-01 Epub Date: 2007-12-22 DOI: 10.1016/S1098-3597(07)80013-5

引用次数: 0

CME test questions cardiometabolic risk and risk management CME测试问题心脏代谢风险和风险管理

Clinical cornerstone Pub Date : 2007-01-01 Epub Date: 2008-04-29 DOI: 10.1016/S1098-3597(07)80032-9

引用次数: 0

Metabolic consequences of hyperglycemia and insulin resistance 高血糖和胰岛素抵抗的代谢后果

Clinical cornerstone Pub Date : 2007-01-01 Epub Date: 2007-12-23 DOI: 10.1016/S1098-3597(07)80019-6

Paul S. Jellinger MD, MACE

{"title":"Metabolic consequences of hyperglycemia and insulin resistance","authors":"Paul S. Jellinger MD, MACE","doi":"10.1016/S1098-3597(07)80019-6","DOIUrl":"10.1016/S1098-3597(07)80019-6","url":null,"abstract":"<div><p>Insulin is a pleiotropic hormone that exerts a multitude of effects on metabolism and various cellular processes in the body. The main metabolic actions of insulin are to stimulate glucose uptake in skeletal muscle and the heart and to suppress the production of glucose and very-low-density lipoprotein in the liver. Other metabolic effects of insulin include inhibition of glucose release from the liver, inhibition of the release of free fatty acids (FFAs) from adipose tissue, and stimulation of the process by which amino acids are incorporated into protein. Insulin resistance (IR) is a condition in which defects in the action of insulin are such that normal levels of insulin do not trigger the signal for glucose absorption. An excess of FFAs is implicated in the pathogenesis of IR. The effects of this condition can have profound pathophysiologic effects on various organs and tissues of the body. For example, IR is associated with impaired insulin signaling, impaired fibrinolysis, and inflammation. The clinical consequences include hyperglycemia-induced tissue damage, hypertension, dyslipidemia, metabolic syndrome, and cardiovascular disease. Pharmacotherapies that target IR include metformin and the thiazolidinediones. Endocannabinoid antagonists, agents that target obesity and associated cardiovascular and metabolic risk factors, are currently being developed.</p></div>","PeriodicalId":80265,"journal":{"name":"Clinical cornerstone","volume":"8 ","pages":"Pages S30-S42"},"PeriodicalIF":0.0,"publicationDate":"2007-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S1098-3597(07)80019-6","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"27186704","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Comprehensive management of cardiometabolic risk factors 心脏代谢危险因素的综合管理

Clinical cornerstone Pub Date : 2007-01-01 Epub Date: 2008-04-29 DOI: 10.1016/S1098-3597(07)80029-9

James Early MD

引用次数: 8